Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own1.10% Shs Outstand33.89M Perf Week-2.19%
Market Cap291.97M Forward P/E- EPS next Y-1.74 Insider Trans-0.31% Shs Float31.98M Perf Month1.07%
Income-65.10M PEG- EPS next Q-0.54 Inst Own71.20% Short Float4.56% Perf Quarter-30.01%
Sales- P/S- EPS this Y25.00% Inst Trans-5.45% Short Ratio6.97 Perf Half Y-6.08%
Book/sh3.72 P/B2.28 EPS next Y-28.80% ROA- Target Price- Perf Year-19.60%
Cash/sh4.67 P/C1.82 EPS next 5Y- ROE- 52W Range7.57 - 13.99 Perf YTD-30.92%
Dividend- P/FCF- EPS past 5Y48.20% ROI- 52W High-39.31% Beta1.34
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low12.15% ATR0.52
Employees28 Current Ratio9.70 Sales Q/Q- Oper. Margin- RSI (14)45.66 Volatility8.79% 6.10%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.53 Prev Close8.54
ShortableYes LT Debt/Eq0.25 EarningsMay 06 AMC Payout- Avg Volume209.10K Price8.49
Recom1.00 SMA20-0.50% SMA50-5.61% SMA200-14.82% Volume117,647 Change-0.59%
Jun-26-19Initiated Citigroup Buy $22
Jan-29-19Initiated Robert W. Baird Outperform $47
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
May-10-21 03:41AM  
May-06-21 04:01PM  
02:45PM  
May-03-21 08:00AM  
Apr-29-21 08:00AM  
Apr-22-21 08:00AM  
Mar-24-21 03:55AM  
Mar-09-21 06:25PM  
04:05PM  
Feb-23-21 11:07AM  
08:00AM  
Feb-08-21 08:00AM  
Jan-25-21 08:00AM  
Jan-07-21 08:00AM  
Jan-06-21 11:00AM  
Dec-24-20 06:49AM  
Nov-25-20 08:42AM  
Nov-24-20 03:10PM  
Nov-23-20 08:00AM  
Nov-20-20 05:53PM  
07:37AM  
Nov-17-20 08:00AM  
Nov-16-20 04:05PM  
Nov-11-20 08:00AM  
Nov-05-20 04:05PM  
Nov-02-20 04:30PM  
Oct-16-20 10:01AM  
Oct-15-20 03:24PM  
08:00AM  
Sep-29-20 07:42AM  
Sep-28-20 03:47PM  
03:07PM  
08:00AM  
Sep-15-20 08:54AM  
Sep-09-20 09:36AM  
Sep-01-20 08:00AM  
Aug-31-20 08:00AM  
Aug-19-20 08:49AM  
Aug-17-20 07:40AM  
Aug-06-20 04:05PM  
Aug-03-20 08:00AM  
Jul-17-20 12:16PM  
Jul-12-20 08:14PM  
Jul-08-20 12:00PM  
Jun-24-20 08:32AM  
Jun-08-20 01:22PM  
May-29-20 04:05PM  
May-26-20 04:05PM  
May-19-20 04:05PM  
May-15-20 08:57AM  
Apr-30-20 08:00AM  
Apr-22-20 10:05AM  
Apr-09-20 06:08PM  
Apr-01-20 04:05PM  
Mar-24-20 10:25AM  
Mar-23-20 08:00AM  
Mar-20-20 06:45AM  
Mar-13-20 08:00AM  
Jan-19-20 03:04PM  
Jan-15-20 05:24AM  
Jan-07-20 08:00AM  
Jan-06-20 08:00AM  
Dec-16-19 05:15PM  
Dec-07-19 01:33AM  
Nov-15-19 08:00AM  
Nov-12-19 08:45AM  
Nov-11-19 09:58AM  
Nov-07-19 04:05PM  
Oct-21-19 09:00AM  
Oct-09-19 09:47AM  
Sep-27-19 08:00AM  
Aug-29-19 04:05PM  
Aug-20-19 08:00AM  
Aug-08-19 04:05PM  
Aug-05-19 08:00AM  
Jul-31-19 08:00AM  
Jul-18-19 09:20AM  
Jul-11-19 12:42PM  
Jul-08-19 09:00AM  
Jun-20-19 07:08PM  
Jun-18-19 07:31AM  
Jun-17-19 04:16PM  
Jun-10-19 08:00AM  
Jun-05-19 08:00AM  
May-30-19 08:00AM  
May-17-19 04:05PM  
May-09-19 05:04PM  
04:01PM  
Apr-30-19 08:00AM  
Apr-26-19 02:43PM  
Apr-23-19 03:50PM  
Apr-17-19 10:53PM  
04:01PM  
Apr-15-19 08:00AM  
Apr-11-19 04:05PM  
Mar-26-19 08:00AM  
Mar-25-19 01:30PM  
Mar-20-19 08:00AM  
Mar-15-19 09:04AM  
Mar-14-19 04:19PM  
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dietz Thomas JohnDirectorApr 09Buy8.492,50021,22037,500Apr 12 06:10 PM
Loh EvanDirectorMar 15Sale10.142,00020,2808,000Mar 15 07:30 PM
Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerJan 08Sale11.681,69019,73935,810Jan 11 06:10 PM
Glenn Jeffrey SDirectorAug 12Buy11.425,00057,1035,000Aug 12 06:28 PM
Glenn Jeffrey SDirectorAug 11Buy11.495,00057,46371,355Aug 12 06:28 PM